Roche Forms Strategic Partnerships with Indian Businesses!
To create comprehensive network of care to bring true relief to Persons with Diabetes
- Digital coaching, therapy: Phable and Wellthy Therapeutics
- E-commerce and Logistics: PharmEasy, Parekh Integrated Services Pvt. Ltd. and Udaan
Chennai, 3rd September 2020 – Roche Diabetes Care (RDC) India recently entered into strategic alliance with Indian partners to fulfil its commitment of providing true relief to persons with diabetes (PwD) through integrated Personalised Diabetes Management (iPDM) solutions. These are part of the company’s public-private-partnership model to create a holistic eco-system of care for PwDs by joining hands with like-minded partners.
The company has partnered with emerging Indian business such as Phable, Wellthy Therapeutics and PharmEasy to bolster its outreach to the PwDs. Through its partnership with Phable, women with GDM using Accu-Chek meters will now have access to a healthcare practitioner (HCP) to monitor their diabetes closely and make necessary therapy titrations via the PhableCare app. This helps improve clinical outcomes and leads to deliveries with fewer complications.
Renewing its existing partnership with Wellthy Therapeutics, the company is now offering its Accu-Chek Active users remote access to personalized coaching from highly skilled diabetes educators, round-the-clock support based on individual needs, and implementation of goal-and-condition based diabetes management plans to improve self-care behaviors for better health outcomes.
Through the partnership with PharmEasy, RDC India has enhanced customer service by addressing key customer pain points. The new start up ecosystem has brought in process agility, thereby creating customer delight.
To strengthen and optimize its distribution channels, the company has partnered with Udaan, a B2B e-commerce platform that enables retailers and businesses to source merchandise from manufacturers, brands, white labels, importers, etc. across the country, on a single platform. The tech-enabled national distribution model of Udaan will help RDC India bring agility and transparency in managing their primary and secondary distribution. The model will be implemented throughout the country in a phased out manner.
Earlier this week Roche Diabetes Care India inaugurated the kit assembly site with Parekh Integrated Services Pvt. Ltd. (PISPL). This new kit assembly site is best in class facility compliant with Roche Global Quality & Safety standards and will assemble and pack blood glucose monitoring kits to fulfill India sales demand. As a strategic partner, PISPL will provide quality manpower and management system for the site.
Speaking about the developments, Omar Sherief Mohammad, Country Head, Roche Diabetes Care India, said, “At Roche we are committed to provide Persons with Diabetes (PwD) comprehensive diabetes management through innovative Integrated Personalised Diabetes Management(iPDM) solutions. In this journey we have chosen to partner with like-minded Indian companies who are doing path-breaking work to create innovative platforms that enable optimal personalised diabetes management and improve therapy outcomes. I am confident that together we can bring true relief to PwDs so that they can spend more time in range.”
The current pandemic and lockdowns have limited patients’ access to healthcare facilities, thereby limiting their proper management and care. Persons with diabetes with uncontrolled blood sugar levels are at a higher risk due to lower immune response2,3. Hence, it is extremely important for persons with diabetes to remain vigilant about their sugar levels and maintain a good glycemic control4.
Through these partnerships, RDC India hopes to empower patients to manage their diabetes better while enabling access to uninterrupted care. Given the increased adoption of digital health solutions in India, RDC India believes the collaboration of like-minded industry partners will be crucial to the overall disease management ecosystem.
References:
[1] Krishnakumar A, Kumar V, Saboo BD, Khatry V, Joshi S, Adhikary R., Impact of Using a Digital Therapeutic and Blood Glucose Meter on Glycemic Control and Variability. Diabetes 2020 Jun; 69(Supplement 1).
[2] Burekovic A, Dizdarevic-Bostandzic A, Godinjak A. Poorly Regulated Blood Glucose in Diabetic Patients-predictor of Acute Infections. Med Arch. 2014 Jun;68(3):163-6.
[3] Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012;16 Suppl 1(Suppl1):S27–S36.
[4] Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020 Mar 10;14(3):211-212.
About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualise relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr one of the most popular diabetes management apps is part of Roche Diabetes Care.
For more information, please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
